¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ¿¼²©±¨°à ÿÈÕÇ©µ½
   
Ö÷Ìâ : µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ
¼¶±ð: ³õ¼¶²©ÓÑ
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-04-19   

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ ѧ¿Æ×¨Òµ£º 1 @q"rPE^  
Aj"fkY|Q  
´«È¾²¡Ñ§ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ LUA<N:  
"iuNYM5 P  
Ò». Ãû´Ê½âÊÍ(ÿÌâ4·Ö,¹²32·Ö) %eJE@$  
X1&c?T1 %[  
1. ICAM-1 IG4`f~k^  
}t1J`+x%  
2. interleukin 12(IL-12) r@G34Q C+  
uh3<%9#\k  
3. tumor infiltrating lymphocyte X7)B)r}AG  
T{*!.+E  
4. TCR/CD3 complex mzn#4;m$  
#mRT>]di`D  
5. hematopoietin receptor family H|<Zm:.%$  
7Dz-xM_?  
6. individual idiotype(IdI) 28lor&Cc  
v3r<kNW_  
7. integrin E7@m& R  
fh9w5hT={  
8. colony-stimulatory factor (CSF) #$ ,b )Uy  
'I@l$H  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© Uq(fk9`6  
32K  
1. ÃâÒßÇòµ°°×ÖØÁ´µÄ»ùÒòÈçºÎ½øÐÐÀà±ðת»»(class switching )? Ji0FHa_  
_O`s;oc  
2. ¼òÊöɱÉËÐÔTϸ°û(Tc)ɱÉ˲¡¶¾¸ÐȾ°Ðϸ°ûµÄ»úÀí¡£ ,xy$h }g  
Jmun^Q/h  
3. ÉúÎïÓ¦´ðµ÷½Ú¼Á( biological response modifier,BRM)Ö÷ÒªÓÐÄļ¸Àà?¼òÒª½éÉÜÔÚ´«È¾ÐÔ¼²²¡·ÀÖÎÖеÄ×÷Óᣠd{(NeTs  
n?8xRaEf  
4. ¼òÊö¿¹Ô­Ìá³Êϸ°û(APC)Ó븨ÖúÐÔTϸ°û(Th)Ï໥×÷ÓõĹØÏµ¡£ v =E(U4v9e  
'~AR|8q?  
Èý. ÎÊ´ðÌâ(ÿÌâ18·Ö,¹²36·Ö) ^8 cq qu  
e9rgJJ  
1. ÊÔÊö¸ÉÈÅËØµÄ·ÖÀ༰ÆäÉúÎïѧ×÷ÓÃÌØµã¡£Ö÷Òª¿ÉÒÔÖÎÁÆÄÄЩ´«È¾ÐÔ¼²²¡?¼òÊö¸ÉÈÅËØ¼ì²âµÄ·½·¨ºÍÔ­Àí¡£ [(Ihue  
ZO]P9b  
2. ºÎΪ»ùÒò¹¤³Ì¿¹Ìå?Ŀǰ¹úÄÚÍâÔÚ»ùÒò¹¤³Ì¿¹ÌåÑо¿ÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? µÚËľüÒ½´óѧһ¾Å¾ÅÈýÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: ´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 1. CD4 2. T cell receptor(TCR) i?'|}tK  
,y[8Vz?:  
3. immunoglobulin superfamily (IgSF) $[+)N ~  
Pk&sY'  
4. selectin uevhW  
#?7g_  
5. anti-idiotypic antibody (¦ÁId) lF3wTf/j  
wfQImCZ>l  
6. major histocompatibility complex(MHC) xi15B5 _Ps  
QQ./!   
7. immunotolerance "$A5:1;  
R#HX}[Hb  
8. biological reponse modifier(BRM) `a9iq>   
|P7FP mn  
9. immune reponse gene (Ir gene) Sgn<=8,6c  
Te7xj8<  
10. reshaped antibody (or reconstituted antibody) Q 6dqFnz  
KxQMPtHstz  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© &o'$uLF~Y  
5'n$aFqI  
1. ¼òÊö°×ϸ°û½éËØ6(IL-6)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¡£ Zhc99L&K  
E_Fm5zb?X  
2. ϸ°û¶¾ÐÔTÁܰÍϸ°û(Tc»òCTL)Ó뿹ÌåÒÀÀµµÄϸ°û½éµ¼µÄϸ°û¶¾(ADCC)ɱÉË»úÀíÓкβ»Í¬? 5jH r?C  
Z=(Tq1t  
3. ¼òÊöµÚ¢ôÐÍ(³Ù·¢ÐÍ)±ä̬·´Ó¦µÄ·¢Éú»úÀí¡£ hp}JKj@  
+6:jm54  
4. NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄ±íÃæ±ê¼Ç?NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄÉúÎïѧ»îÐÔ? e//jd&G  
~%@1-  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö) ¹©´«È¾²¡Ñ§×¨ÒµÊÔÌ⣺ $>rKm  
-x-EU#.G  
1. »úÌåÓÐÄÄЩÃâÒßϸ°ûºÍÃâÒß·Ö×Ó²ÎÓ뿹²¡¶¾¸ÐȾ?ËüÃÇÊÇÈçºÎ·¢»Ó²¡¶¾ÃâÒß×÷ÓõÄ? ^ LVKXr  
me$nP}%C&  
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚ²¡¶¾Ñ§ÖÐÓÐÄÄЩÖ÷ÒªÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ r`Dm;@JU  
0KA@ ]!  
¹©Ïû»¯ÄÚ¿Æ×¨ÒµÊÔÌ⣺ A+( + Pf U  
e'.CIspN  
1. ĿǰÌåÄÚºÍÌåÍâ¼ì²âÖ×Áö»¼ÕßÃâÒß¹¦Äܵķ½·¨Ö÷ÒªÓÐÄÄЩ?·Ö±ðÐðÊöÿÖÖ·½·¨µÄÔ­ÀíºÍ½á¹û²â¶¨?  '3xK1Am  
K?>sP%m)  
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚÖ×ÁöѧÖÐÓÐÄÄЩÖ÷ÒªµÄÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ uo bQ S!  
a I 1tG  
µÚËľüÒ½´óѧһ¾Å¾ÅËÄÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: Tt4Q|"CJA  
#X2wy$GTG  
´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: S2>$S^[U  
ha7mXGN%  
ÃâÒßѧ S" (Nf+ux  
w!-MMT4y  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© *'@ sm*  
gZ8JfA_\R(  
1. CD8 YKzfI9Y  
o>|D T(Ib  
2. T cell receptor ¦Á and ¦Â chain (TCR¦Á¦Â ) =,8nfJ+x  
OxUc,%e9P  
3. immunoglobulin fold(Ig fold) Pk=0pHH8q  
Z/d {v:)  
4. cadherin (Ca-dependent cell adhesion moleculers) ^fmuBe}d{  
Rln\  
5. idiotype-anti-idiotypic antibody immune network theory }$LnjwM;,  
^tIYr <I  
6. HLA class II antigen tlB -s;  
4BeHj~~  
7. complementarity-determining region (CDR) [I/ZzDMX  
<'\!  
8. perforin(or pore-forming protein ,PFP) 2#N?WlYw<S  
&P"13]^@  
9. high affinity IL-2 receptor `ZT/lB`  
HDaeJk  
10. artificial active immunization I hv@2{*(b  
|9X2AS Qu  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© ~(B%E'  
0.2stBw  
1. ¼òÊö°×ϸ°û½éËØ2(IL-2)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¼°ÆäÔÚÁÙ´²ÖÎÁÆÖеÄÓ¦Óᣠ]c bXI  
q_98=fyE6  
2. Çë±È½ÏµÚ¢ñÐÍ(ËÙ·¢ÐÍ)³¬Ãô·´Ó¦ÓëµÚ¢ôÐÍ(³Ù·¢ÐÍ)³¬Ãô·´Ó¦µÄ·¢²¡Ìص㡣 Pq@ -`sw  
`g4N]<@z  
3. ÊÔÊö·ÖÃÚÐÍIgA(secretory IgA)µÄ½á¹¹ÌصãºÍºÏ³É·ÖÃÚ¹ý³Ì¡£ _dW#[TCF  
Br.UN~q  
4. ÊԱȽÏT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(Èç±íÃæ¿¹Ô­¡¢±íÃæÊÜÌåµÈ)µÄÒìͬµã¡£ J^S!GG'gb  
$yq76  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö¡£Çë×¢Ò⣺ÿλ¿¼ÉúÖ»ÄÜ´Ó1¡¢2ÌâÖÐѡһÌâ,3¡¢4ÌâÖÐѡһÌâ,¹²´ðÁ½Ìâ,¶à´ðÕß²»¼Æ·Ö¡£) 1. Ŀǰ¼ì²âϸ°ûÒò×ÓÖ÷ÒªÓÐÉúÎïѧ»îÐÔ¼ì²â·¨ºÍÃâÒßѧ¼ì²â·¨,Çë¾ÙÀý·Ö±ðÐðÊöÁ½ÖÖ·½·¨µÄʵÑéÔ­Àí¡£ H9(UzyN>i  
6q!Q(_  
2. ΪÁ˱ÜÃâIgG¿¹ÌåFc¶Î·ÇÌØÒìÐÔ×÷ÓÃ,³£Ó¦ÓÃθµ°°×øˮ½âµÄF(ab¡¯)2¶Î,ÊÔÎÊÈçºÎÓ¦ÓÃSDS-PAGE·½·¨¶ÔF(ab¡¯)2½øÐмø¶¨? [:q J1^UU  
hpYv*WH:  
3. ÊÔÊö¿¹Ö×Áö»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ g3^:)$m  
s,kY12<7m  
4. ÊÔÊö¿¹²¡¶¾»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ ¡¡ N9s.nu  
1ox#hQBoS  
µÚËľüÒ½´óѧһ¾Å¾ÅÎåÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ >< P<k&  
:UAcS^n7h"  
ѧ¿Æ×¨Òµ£ºÃâÒßѧ¡¢´«È¾²¡Ñ§¡¢Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿£ºÃâÒßѧ N U+PG`Vb  
\I^"^'CP  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© [2>zaag  
:eT\XtxM~{  
1. immunoglobulin gene rearrangement D>ou,  
!VsdKG)  
2. the common chain of cytokine receptor (or a cytokine receptor subunit shared by some cytokine receptors) TTbJ9O<43  
p#-=mXE/2  
3. flow cytometry(FCM) nEW.Y33  
DiY74D  
4. carrier effect 5w{U/v$Z  
?<Hgq8J  
5. positive selection of T lymphocytes in thymus 3)9e-@  
'HCRi Z<  
6. mouse TH1(Th1) and TH2(Th2) subsets 9}Za_ZgG  
A7&/3C6{H  
7. perforin (pore-forming protein ,PFP) ' V*}d  
#7]>ozKm  
8. ADCC(antibody-dependent cell-mediated cytotoxicity) wZbT*rU  
O 8N1gf;t  
9. SH-2(src-homology region 2) c* ~0R?  
|nr;OM  
10. Ab2¦Â (internal image) 5|t-CY{?b  
c,ct=m.|6A  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© KL9JA; "  
Dq9f Fe  
1. ½üÄêÀ´ÔÚÈËÀà°×ϸ°û·Ö»¯¿¹Ô­(CD)Ñо¿ÁìÓòÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? <{hB&4oL  
Zm|il9y4m  
2. ²ÎÓë»î»¯Tϸ°ûÓë»î»¯Bϸ°ûÏ໥×÷ÓõķÖ×ÓÖ÷ÒªÓÐÄÄЩ?¼òÊöÆä½á¹¹ºÍ¹¦ÄÜ? $Fy~xMA8O  
n <HF]  
3. ÊÔÊöHLAÔÚÁÙ´²ÉϵÄÖ÷ÒªÓ¦Óᣠ0}'/pN>  
'%:E4oI  
4. Àý¾ÙÈýÖÖ´ÓÈËÍâÖÜѪµ¥¸öºËϸ°û(PBMC)Öд¿»¯Tϸ°ûµÄ·½·¨,·Ö±ðÐðÊöÆäʵÑéÔ­ÀíºÍÖ÷Òª²Ù×÷²½Öè¡£ M19 5[]  
kkj@!1q(wO  
5. ÆÀ¼Ûºìϸ°ûÉú³ÉËØ(EPO)¡¢¸ÉÈÅËØ(IFN)ºÍ¼¯Âä´Ì¼¤Òò×Ó(CSF)ÔÚÁÙ´²Ä³Ð©¼²²¡µÄÓ¦ÓᣠjGJf[:M&Pm  
W?.xtQEv  
Èý. Ñ¡ÔñÎÊ´ðÌâ(ÿÌâ10·Ö,¹²20·Ö¡£Çë°´±¨¿¼×¨Òµ´ðÌâ,Èç´ð·Ç±¾×¨ÒµÌâ»ò¶à´ðÌâ¾ùÊÓΪÎÞЧ¡£) ;ByCtVm2  
N[O_}_  
ÃâÒßѧרҵ£º gh"_,ZhZt  
m}: X\G(6Q  
1. ÊÔÊöϸ°ûÒò×ÓÊÜÌåÖÐ,Ig³¬¼Ò×å¡¢ÔìѪÒò×ÓÊÜÌ峬¼Ò×å¡¢Éñ¾­Éú³¤Òò×ÓÊÜÌ峬¼Ò×åÒÔ¼°Ç÷»¯Òò×ÓÊÜÌ峬¼Ò×åµÄÖ÷Òª½á¹¹Ìصã,ÿ¸ö³¬¼Ò×åÀý¾Ù³ö2¸ö³ÉÔ±¡£ W=|'&UU Ul  
LUz`P6  
2. ÊԱȽÏÈËT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(±íÃæ±ê¼Ç)µÄÒìͬµã,ËüÃÇ·Ö±ð²ÎÓëÄÄЩÖ÷ÒªµÄÃâÒß¹¦ÄÜ? e(`r"RrQ  
~{kA;uw  
´«È¾²¡Ñ§×¨Òµ£º d)XT> &  
6Q+VW_~  
1. ÈËÀàÃâÒßȱÏݲ¡¶¾(HIV)¸ÐȾÈËÌåºó,ÃâÒß¹¦Äܿɷ¢ÉúÄÄЩÖ÷ÒªµÄ±ä»¯?»úÀíÊÇʲô?ÈçºÎ½øÐÐÏàÓ¦µÄÃâÒßѧ¹¦Äܼì²â£¿ 9jl\H6JY|  
C)9-{Yp  
2. ÇëÆÀÊöÉö×ÛºÏÕ÷³öѪÈȲ¡¶¾(HFRSV)¸ÐȾºó»úÌåÃâÒßѧ±ä»¯µÄÓ벡ÀíËðÉ˵ĹØÏµ¡£ ]x3 )OjH  
OT)`)PZ"  
Ïû»¯×¨Òµ£º K+yi_n L  
@OHNz!Lj:d  
1.ÊÔÊöÓëÏû»¯ÏµÍ³ÓйصÄÖ×ÁöÏà¹Ø¿¹Ô­Ñо¿µÄ½øÕ¹¡£ $D f1t  
Gt!Hm(  
2.¼òÊöճĤÏà¹ØÁܰÍÑù×éÖ¯(mucosal assiociated lymphoid tissue,MALT)µÄ×é³ÉºÍ¹¦ÄÜÌØµã¡£·ÖÃÚÐÍIgAÊÇÈçºÎ½øÐкϳɺͷÖÃÚµÄ? Th~pju  
td#m> S  
µÚËľüÒ½´óѧһ¾Å¾ÅÁùÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ÃâÒßѧÊÔÌâ WFqOVI*l  
j{zVVT  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© z:{R4#(Q  
Ac[;S!R  
1. Fas(CD95)/FasL [Kbna>`  
A {')  
2. common chain of cytokine receptor VrFI5_M/  
x6=tS  
3 . TCR/CD3 complex z]O>`50Q  
CR|>?9V  
4. negaive selection of thymocytes |C t Q  
TR{dNO!q  
5. artificial active immune u)ZZ/|  
} x'o`GuUf  
6. anti-idiotypic =E8Kacu%  
HL!"U (_  
7. IgSF nON "+c*  
I,lzyxRP  
8. Integrin Lismo#  
h^b =  
9. chemokine V0:db  
v8A{ q  
10. B7/CD28 E __A1j*gd  
0'*'%Iga  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²60·Ö£© W{;LI WsZ  
>Q^*h}IdW  
1. ±È½ÏMHC¢ñºÍMHC¢òÀ࿹ԭ²ÎÓëµÄ¼Ó¹¤Ìá³Ê¿¹Ô­µÄ¹ý³Ì¡£ H0mDs7  
VnMiZAHR  
2. ±È½ÏCTLºÍNKɱÉ˰Ðϸ°ûʱʶ±ðºÍɱÉË»úÖÆµÄÌØµã¡£ OB ~74}3;  
|n&EbOmgf  
3. ±È½ÏÃâÒßѧ¼ì²â·¨ºÍÉúÎïѧ»îÐÔ¼ì²â·¨¼ì²âϸ°ûÒò×ÓµÄÓÅȱµã¡£ i{/ nHrN  
7PI|~Ifi  
4. ·¢ÏÖÒ»ÖÖеİ×ϸ°û·Ö»¯¿¹Ô­»òÖ×ÁöÏà¹Ø¿¹Ô­,²¢ÖƱ¸Á˵¥¿Ë¡¿¹Ìå,ÊÔÉè¼ÆÊµÑé·½°¸¿Ë¡´Ë»ùÒò¡£ ZbcpE~<a  
w9a6F  
5. Ñ¡ÔñÏÂÊöÖÐÒ»¸öרÌâ,ÐðÊöÎÒ¹úÔÚÕâÒ»Ñо¿ÁìÓòµÄÏÖ×´¼°ÃæÁÙµÄÌôÕ½1)Ö×ÁöÃâÒߣ»(2)»ùÒòÖÎÁÆ£»(3)CD¿¹Ô­¡£ SkA"MhX  
%bUpVyi!(  
µÚËľüÒ½´óѧһ¾Å¾ÅÆßÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÃâÒßѧÊÔÌâ JTB5#S4W  
aA.TlG@zP  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© r7p>`>_Q\  
9Uh nr]J.  
1. B7/CD28 cb~m==G  
U z6XQskX  
2. Th1 subset |4a#O8d  
sWnU*Q  
3. seven predicated transmembrane domain receptor superfamily£¨STR superfamily£© Zx]"2U#  
2]*2b{gF,  
4. antibody affinity maturation `_v|O{DC{  
z '%Vy  
5. AP-1 xTL"%'|  
07+Qai-]  
6. single chain variable fragment£¨ScFv£© W;C41>^?/  
1jozM"H7Q  
7. NK cell receptor _\LAWQ|M4[  
X;0DQnAI8j  
8. Zinkernagel-Doherty phenomenon YvK8;<k@-?  
OsR4oT  
9. Ig fold Pw'3ya8  
MLc c   
10. CD40/CD40L I%whM~M1+  
X@)5F 9  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²36·Ö£© mPxph>o  
pRj1b^F5y  
1. ÊÔÊöÐØÏÙ΢»·¾³¶ÔÐØÏÙϸ°ûµÄÑ¡Ôñ×÷Óü°ÆäÓëTϸ°û¹¦ÄÜÐÔÑÇȺÐγɵĹØÏµ¡£ Dw^d!%Ala  
_S#uxgL<  
2. ÊÔÊöÌåÒºÃâÒßÓ¦´ðµÄ¹æÂÉ£¬»ØÒä·´Ó¦ºÍ¿¹ÌåÀà±ðת»»µÄ»úÖÆÊÇʲô£¿ b^\u P  
vd9><W  
3. ÊԴӽṹºÍ¹¦ÄܵȽǶȣ¬²ûÊö°×ϸ°û·Ö»¯¿¹Ô­£¨CD£©¡¢Õ³¸½·Ö×Ó£¨integrin£©ºÍÃâÒßÇòµ°°×³¬¼Ò×壨IgSF£©ÈýÀà·Ö×ÓµÄÏ໥¹ØÏµ¡£Ä¿Ç°ÔÚÕâÒ»ÁìÓòÖÐÖ÷ÒªÑо¿ÈȵãÊÇʲô£¿ l M5Xw  
s7<x~v+^  
Èý. ÎÊ´ðÌ⣨24·Ö£¬µÚ1ÌâΪÃâÒßѧרҵ¿¼ÉúÊÔÌ⣬µÚ2ÌâΪѪҺ²¡Ñ§¿Æ¿¼ÉúÊÔÌ⣬µÚ3ÌâΪÏû»¯ÄÚ¿Æ¿¼ÉúÊÔÌ⣬ֻÔÊÐí´ð±¾×¨ÒµÊÔÌ⣩ R I"A'/56  
W9?Vh{w  
1. ÊԱȽÏTCRºÍBCR½á¹¹¼°Æäʶ±ð¿¹Ô­¡¢ÁܰÍϸ°û»î»¯ÐźŵķÖ×Ó»úÀí¡££¨ÃâÒßѧרҵ£©¡£ cSBYC_LU  
+I7n6s\  
2. ÊÔÊö°×Ѫ²¡ÃâÒßѧ·ÖÐÍÀíÂۺͷ½·¨µÄÑо¿½øÕ¹¡££¨ÑªÒº²¡Ñ§×¨Òµ£©¡£ nJ4i[j8  
=$IjN v(?  
3. ÊÔÊöÖ×ÁöÒßÃçµÄÑо¿½øÕ¹¡££¨Ïû»¯ÄÚ¿Æ×¨Òµ£©¡£ -Vk+zEht  
A\_cGM2  
Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ £¨ÃâÒßѧרҵºÍרҵ»ù´¡£© _rK}~y=0  
B`} ?rp  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© 4QZ -7_  
mV} peb  
1.Co-stimulators (or co-stimulating molecules) T"XP`gk  
J A ]s  
2.NK-kB INsc!xOQ  
GM{m(Y  
3.Immunoglobulin superfamily 7^h?<X\  
|Z<NM#1  
4.antigen-presenting cell (APC) a 1Qg&s<  
{mMrD 5  
5.death domain n0kBLn  
zo&'2I  
6.CCR and CXCR ig] * Z  
 ;OQ{  
7.Lectin (or mitogen) Funep[rA  
!dYkvoQNn  
8.Clusters of differentiation, CD) DF/p{s1Y3  
MVK='  
9.B7 family WaQ Cq0Enj  
<P7f\$o~  
10.Cytotoxic T lymphocyte, CTL) SJ;u,XyWn  
FJgr=9>  
11.IL-15 and IL-15 receptor (IL-15R) l2U"4d!o  
7\'vSHIL  
12.MHC restriction 3Ln~"HwP  
2c@R!*  
13.Affinity-chromatography z@^[.  
C] qY  
14.Cyctosprin A, CsA &i4*tE3],  
7OYNH0EH  
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) C 2Fklp6  
h}i /u  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© }x`W+r  
N&U=5c`Q'  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 (p'yya{(  
A9ia[2[  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ q [Rqy !,  
PuqT&|wP l  
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌØµã¡£ -$J\BkI  
,J"6(nk  
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© rlmzbIu I9  
k{(R.gLZG  
ÃâÒßѧרҵ£º YwyP+S r\  
(wU<Kpt?J  
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ xV[X#.3  
n~l9`4wJY  
Ïû»¯ÄÚ¿Æ£º 2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ NypM+y  
zD:"O4ZM^^  
ѪҺ²¡Ñ§×¨Òµ£º 3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿ kg?[   
A94ZG:   
Ò»¾Å¾ÅÄê¾Å²©Ê¿ÉúÈëѧ¿¼ÊÔÊÔÌâ (רҵ»ù´¡: ÃâÒßѧ) bhDV U(%I6  
D*BZp0x  
Ò».Ãû´Ê½âÊÍ(ÿÌâ5·Ö,¹²45·Ö) W~ (@*H  
Rd@34"O  
1. ADCC(antibody dependent cell-mediated cytotoxicity) QPB@qx#@  
EjW3_ %  
2. »·æß¾úËØ(cyclosporin) EITA[Ba B`  
/|V!2dQs"  
3. KIR(killer cell inhibitory receptor) ^F2 OTz4n  
CZ"~N`  
4. HLDA(human leucocyte differentiation antigen) $Wt0e 4YSu  
l]t9*a]a  
5. Interleukin 18(IL-18) A2>rS   
gv)F`uRWA  
6. ÕûºÏËØ(integrin) w/_n$hX  
" !43,!<  
7. Fas/FasL ,p2BB"^_i  
"c5C0 pK0  
8. FcR(ÃâÒßÇòµ°°×Fc¶ÎÊÜÌå) ZS&>%G  
uG<VQ2LM  
9. ϸ°û¼äÕ³¸½·Ö×Ó(ICAM) >Y,3EI\  
GZJIIP#  
10. Th1/Th2 ?^y%UIzf  
X 'D~#r  
11. »ùÒòÒßÃç(DNAÒßÃç) ;VM',40  
&%J+d"n(  
12. chemokines and chemokine receptor a(Q4*XH4  
">pW:apl%  
13. ÃâÒßÄÍÊÜ F>N3GPRl  
}{FKs!(4  
14. ¹²´Ì¼¤·Ö×Ó C-25\  
9J>b6   
15. ËÀÍö½á¹¹Óò(death domain) F.;G6  
J6m`XC  
¶þ.ÎÊ´ðÌâ(µÚ1¡¢2Ìâ¸÷18·Ö,µÚ3Ìâ19·Ö) [HEqMBX=;  
38Rod]\E  
1. ÊԱȽÏɱÉËÐÔTϸ°û(CTL)Óë×ÔȻɱÉËϸ°û(NK)ÔÚɱÉ˰Ðϸ°û¹ý³ÌÖÐ,ʶ±ðϸ°û¶¾¼°½éµ¼ÃâÒß¹¦ÄÜÓкβ»Í¬? si`{>e~`6P  
gkxEy5c[  
2. 70Äê´úÒÔÀ´,ÓйØIgºÍÌåÒºÃâÒßÑо¿´æÔÚÒÔϼ¸ÏîÖØ´ó·¢ÏÖºÍÍ»ÆÆ¶ø»ñµÃҽѧºÍÉúÎïѧŵ±´¶û½±,Çë·Ö±ð²ûÊöËüÃǵÄÀíÂÛÒâÒå¼°ÔÚҽѧʵ¼ùÖеÄÓ¦Óᣠ7\.Ax  
 ?gZJ v  
£¨1£©1972Ä꣺θµ°°×øºÍľ¹Ïµ°°×øˮ½âIg£¬»ñµÃFab¡¢Fc¡¢F£¨ab¡¯£©2µÈƬ¶Î /cmnX'z  
aFkxR\x 6%  
£¨2£©1977Ä꣺·ÅÉäÃâÒß·¨ /  D9FjOP  
6 yIl)5/=  
£¨3£©1984Ä꣺ÁܰÍϸ°ûÔÓ½»ÁöºÍµ¥¿Ë¡¿¹Ìå $`nKq4Y   
#3uBq(-Z  
£¨4£©1987Äê: Ig»ùÒòµÄ½á¹¹ 3. ½üÄêÀ´ÔÚÖ×ÁöÃâÒßÑо¿ÁìÓòÖÐÓÐÄÄÐ©ÖØÒª½øÕ¹?ÊÔÊöµ±Ç°Ìá¸ß»úÌ忹Ö×ÁöÃâÒßµÄÖ÷Òª²ßÂÔ¡£ ZqI.n4:9  
IKJ~sw~AQ  
Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(ÃâÒßѧרҵ) ÎÊ´ðÌâ(ÿÌâ25·Ö) {d|R67~V  
~cE;k@  
1. ÊԱȽÏTϸ°ûÊÜÌ壨TCR£©¡¢Bϸ°ûÊÜÌ壨BCR£©ºÍNKϸ°ûÊÜÌ壨NKCR£©µÄ×é³É£¬Ê¶±ðÅäÌåÒÔ¼°ÐźÅתµ¼µÄÒìͬµã¡£ ,gU%%>-_~w  
,+p&ZpH  
2. ÒÔÐØÏÙÒÀÀµ¿¹Ô­´Ì¼¤»úÌå²úÉú¿¹ÌåµÄÃâÒßÓ¦´ðΪÀý£¬Tϸ°ûºÍBϸ°ûÊÇÈçºÎÏ໥×÷Óã¿ÓÐÄÄЩճ¸½·Ö×Ӻ͹²´Ì¼¤·Ö×Ó²ÎÓëT¡¢Bϸ°ûµÄÏ໥×÷Óã¿ x,9fO A  
uj.~/W1,!  
3. Éö×ÛºÏÕ÷³öѪÈÈ(HFRS)²¡¶¾µÄ½á¹¹»ùÒòÒѾ­¸ãÇå³þ,ΪÁË֤ʵHFRS²¡¶¾¸ÐȾ»úÌå(ÒÔBalb/CСÊóΪÀý)¿É²úÉúHFRS²¡¶¾ºËÒ¿ǵ°°×(NP)ÌØÒìÐÔCTL,²¢ÔÚÃâÒß·À»¤ÖÐÆðÖØÒª×÷ÓÃ,ÇëÓ¦ÓÃÃâÒßѧÀíÂۺͷ½·¨,Éè¼ÆÒ»ÏµÍ³ÊµÑé,¼ÓÒÔ֤ʵ¡£ 4. Àý¾Ù¶þ¸ö½üÄêÀ´Ï¸°ûºÍ·Ö×ÓÃâÒßѧÑо¿ÖгöÏÖµÄеÄÈȵã,Çë·Ö±ðÆÀÊöÆäÑо¿ÒâÒå¡¢·¢Õ¹Ç÷ÊÆÒÔ¼°Ó¦ÓÃǰ¾°¡£
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
4+6=? ÕýÈ·´ð°¸:10
°´"Ctrl+Enter"Ö±½ÓÌá½»